Outcome of patients with non-hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 6, 2015, Pages 341-348

  Sun, Haowei ^a   Savage, Kerry J ^b   Karsan, Aly ^b   Slack, Graham W ^b   Gascoyne, Randy D ^b   Toze, Cynthia L ^a,c   Sehn, Laurie H ^b   Abou Mourad, Yasser ^a,c   Barnett, Michael J ^a,c   Broady, Raewyn C ^a,c   Connors, Joseph M ^b   Forrest, Donna L ^a,c   Gerrie, Alina S ^a,b,c   Hogge, Donna E ^a,c   Narayanan, Sujaatha ^a,c   Nevill, Thomas J ^a,c   Nantel, Stephen H ^a,c   Power, Maryse M ^a,c   Sutherland, Heather J ^a,c   Villa, Diego ^b   Shepherd, John D ^a,c   Song, Kevin W ^a,c   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Aggressive B cell lymphoma; allotransplant; BCLU; Double hit lymphoma; Magrath protocol

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BCL2 GENE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DOUBLE HIT LYMPHOMA; FEMALE; FOLLOW UP; GENE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROTO ONCOGENE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; GENE REARRANGEMENT; GENES, BCL-2; GENES, MYC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84931576036     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.12.015     Document Type: Article

References (20)

1. P.M. Kluin, N.L. Harris, and H. Stein WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 International Agency for Research on Cancer Lyon
2. S.M. Aukema, R. Siebert, and E. Schuuring Double-hit B-cell lymphomas Blood 117 2011 2319 2331
3. N.A. Johnson, K.J. Savage, and O. Ludkovski Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival Blood 114 2009 2273 2279
4. A. Kanungo, L.J. Medeiros, L.V. Abruzzo, and P. Lin Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis Mod Pathol 19 2006 25 33
5. S. Le Gouill, P. Talmant, and C. Touzeau The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement Haematologica 92 2007 1335 1342
6. N. Niitsu, M. Okamoto, I. Miura, and M. Hirano Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations Leukemia 23 2009 777 783
7. M.O. Pedersen, A.O. Gang, and T.S. Poulsen Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience Eur J Haematol 89 2012 63 71
8. M. Snuderl, O.K. Kolman, and Y.B. Chen B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma Am J Surg Pathol 34 2010 327 340
9. N. Tomita, M. Tokunaka, and N. Nakamura Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations Haematologica 94 2009 935 943
10. S. Li, P. Lin, and L.E. Fayad B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome Mod Pathol 25 2012 145 156
11. A.M. Petrich, M. Gandhi, and B. Jovanovic Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis Blood 124 2014 2354 2361
12. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
13. A. Lacasce, O. Howard, and S. Lib Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity Leuk Lymphoma 45 2004 761 767
14. J. Tsai, J.P. Greer, and D.S. Morgan Role of aggressive chemotherapeutic regimens in double hit lymphoma- can alternate aggressive induction regimens overcome the poor prognosis of diffuse large B-cell lymphoma (abstract 4361) Blood 122 2013
15. C. Howlett, A. Goy, and T. Zielonka Dose intensive induction followed by allogeneic stem cell transplantation more than doubles progression-free and overall survival in "double-hit" lymphoma (DHL) (abstract 2141) Blood 122 2013
16. N. Macpherson, D. Lesack, and R. Klasa Small noncleaved, non-Burkitt (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation J Clin Oncol 17 1999 1558 1567
17. J.B. Cohen, S.M. Geyer, and G. Lozanski Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival Cancer 120 2014 1677 1685
18. Y. Oki, M. Noorani, and P. Lin Double hit lymphoma: the MD Anderson Cancer Center clinical experience Br J Haematol 166 2014 891 901
19. M. Greenwood, T. Armytage, and K. Fay Outcomes of allogeneic stem cell transplantation for non-Hodgkin lymphoma with concurrent MYC and BCL2 translocations: a single centre retrospecive analysis (abstract 24) Hematol Oncol 31 2013 103 104
20. M.O. Pedersen, A.O. Gang, and T.S. Poulsen MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations Eur J Haematol 92 2014 42 48